Development of a validated HPLC method for simultaneous determination of olanzapine and aripiprazole in human plasma

Sakine Atila Karaca; Duygu Yeniceli Uğur

Makale detayları

Development of a validated HPLC method for simultaneous determination of olanzapine and aripiprazole in human plasma

Yazarlar:

Sakine Atila Karaca | Duygu Yeniceli Uğur

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Analytical Chemistry

Dergi:

Journal of Research in Pharmacy Vol.22 Issue 4, pp.493-501

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001346463

pISSN:

2630-6344

Anahtar kelimeler:

Özet:

 A simple and rapid HPLC method was developed and validated for simultaneous determination of two antipsychotic drugs, olanzapine and aripiprazole, in spiked human plasma. Optimization studies were performed using experimental design approach. The most important analysis parameters were selected using fractional factorial design and optimum levels of these parameters were determined with Box-Behnken design. Separation was achieved on a monolithic column Rp-18, 100-4.6 mm set at 35C with a flow rate of 0.8 mlmin. Gradient elution was performed with a mobile phase consisting of phosphate buffer pH 3.14, 20 mM and acetonitrile. Retention times of olanzapine and aripiprazole were 2.34 and 6.90 minutes, respectively. The method was linear in the range of 0.125-50.0 µgml for olanzapine and 0.500-50.0 µgml for aripiprazole. The quantification limits for olanzapine and aripiprazole were found 0.069 and 0.498 µgml, respectively. The method was found accurate and precise based on recovery values, which were between 99-102 and relative standard deviations, which were lower than 2. Robustness of the method and the stability of analytes were also investigated.

 A simple and rapid HPLC method was developed and validated for simultaneous determination of two antipsychotic drugs, olanzapine and aripiprazole, in spiked human plasma. Optimization studies were performed using experimental design approach. The most important analysis parameters were selected using fractional factorial design and optimum levels of these parameters were determined with Box-Behnken design. Separation was achieved on a monolithic column Rp-18, 100-4.6 mm set at 35C with a flow rate of 0.8 mlmin. Gradient elution was performed with a mobile phase consisting of phosphate buffer pH 3.14, 20 mM and acetonitrile. Retention times of olanzapine and aripiprazole were 2.34 and 6.90 minutes, respectively. The method was linear in the range of 0.125-50.0 µgml for olanzapine and 0.500-50.0 µgml for aripiprazole. The quantification limits for olanzapine and aripiprazole were found 0.069 and 0.498 µgml, respectively. The method was found accurate and precise based on recovery values, which were between 99-102 and relative standard deviations, which were lower than 2. Robustness of the method and the stability of analytes were also investigated.

 A simple and rapid HPLC method was developed and validated for simultaneous determination of two antipsychotic drugs, olanzapine and aripiprazole, in spiked human plasma. Optimization studies were performed using experimental design approach. The most important analysis parameters were selected using fractional factorial design and optimum levels of these parameters were determined with Box-Behnken design. Separation was achieved on a monolithic column Rp-18, 100-4.6 mm set at 35C with a flow rate of 0.8 mlmin. Gradient elution was performed with a mobile phase consisting of phosphate buffer pH 3.14, 20 mM and acetonitrile. Retention times of olanzapine and aripiprazole were 2.34 and 6.90 minutes, respectively. The method was linear in the range of 0.125-50.0 µgml for olanzapine and 0.500-50.0 µgml for aripiprazole. The quantification limits for olanzapine and aripiprazole were found 0.069 and 0.498 µgml, respectively. The method was found accurate and precise based on recovery values, which were between 99-102 and relative standard deviations, which were lower than 2. Robustness of the method and the stability of analytes were also investigated.

 A simple and rapid HPLC method was developed and validated for simultaneous determination of two antipsychotic drugs, olanzapine and aripiprazole, in spiked human plasma. Optimization studies were performed using experimental design approach. The most important analysis parameters were selected using fractional factorial design and optimum levels of these parameters were determined with Box-Behnken design. Separation was achieved on a monolithic column Rp-18, 100-4.6 mm set at 35C with a flow rate of 0.8 mlmin. Gradient elution was performed with a mobile phase consisting of phosphate buffer pH 3.14, 20 mM and acetonitrile. Retention times of olanzapine and aripiprazole were 2.34 and 6.90 minutes, respectively. The method was linear in the range of 0.125-50.0 µgml for olanzapine and 0.500-50.0 µgml for aripiprazole. The quantification limits for olanzapine and aripiprazole were found 0.069 and 0.498 µgml, respectively. The method was found accurate and precise based on recovery values, which were between 99-102 and relative standard deviations, which were lower than 2. Robustness of the method and the stability of analytes were also investigated.

Makale detayları

Development of a validated HPLC method for simultaneous determination of olanzapine and aripiprazole in human plasma

Yazarlar: Sakine Atila Karaca | Duygu Yeniceli Uğur

Yayıncı: Marmara University

Ana Başlıklar: Pharmaceutical Analytical Chemistry

Dergi: Journal of Research in Pharmacy Vol.22 Issue 4, pp.493-501

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001346463

pISSN: 2630-6344

olanzapine

aripiprazole

HPLC

determination

experimental design

human plasma

Sayı

Yazarlar:

Sakine Atila Karaca | Duygu Yeniceli Uğur

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Analytical Chemistry

Dergi:

Journal of Research in Pharmacy Vol.22 Issue 4, pp.493-501

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001346463

pISSN:

2630-6344